Biosimilar Newsletter Archive

  1. 02.02.23 -- Maximizing Cell Culture Productivity 2/2/2023

    02/02/23 Biosimilar Development Newsletter

  2. 02.02.23 -- Why Location Matters In CDMO Selection 2/2/2023
    02/02/23 Biosimilar Development Newsletter
  3. 01.26.23 -- Make The Service Agreement Work For You And Your CDMO 1/26/2023
    01/26/23 Biosimilar Development Newsletter
  4. 01.20.23 -- De-Risking Combination Product Development For Biosimilars 1/20/2023

    01/20/23 Biosimilar Development Newsletter

  5. 01.19.23 -- 4 Key Takeaways For Combination Products As We Move Into 2023 1/19/2023
    01/19/23 Biosimilar Development Newsletter
  6. 01.12.23 -- FDA Accepts Stelara Biosimilar BLA For Review 1/12/2023
    01/12/23 Biosimilar Development Newsletter
  7. 01.05.23 -- Where Do We Stand On Adopting Continuous Manufacturing For Biologics? 1/5/2023
    01/05/23 Biosimilar Development Newsletter
  8. 12.22.22 -- FDA Accepts Biogen BLA For Biosimilar Actemra 12/22/2022
    12/22/22 Biosimilar Development Newsletter
  9. 12.15.22 -- ACMA Develops Board-Certified Biologics & Biosimilars Specialist Certification 12/15/2022
    12/15/22 Biosimilar Development Newsletter
  10. 12.12.22 -- Don't Miss 6 Key Topics That Changed Biopharma Testing In 2022 12/12/2022

    12/12/22 Biosimilar Development Newsletter